
The Simplify High Yield ETF (CDX) is engineered to generate substantial current income. It achieves this by primarily allocating its capital to high-yield bonds, while simultaneously deploying strategies to reduce inherent credit risk. CDX offers foundational exposure to the high-yield market, delivering appealing income streams, and is fortified by a diverse array of dynamic and effective credit hedging techniques. Its principal hedging mechanism is rooted in a Quality-Junk factor. Furthermore, the ETF opportunistically invests in CDX call options and equity put options, assessing opportunities based on advantageous cost-to-payout ratios.
Is CDX's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.

HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today presented positive results from the Phase 1 healthy participant study of CDX-622, a novel, bispecific antibody that targets soluble SCF and TSLP, at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. Data demonstrated that CDX-622 induced rapid, durable, dose-dependent reductions in serum tryptase, indicative of mast cell depletion, and was well-tolerated at all dose levels. Building on Celldex's leadership in mast cell science, the data also demonstrated that neutralizing soluble stem cell factor (SCF) enables the potential for meaningful mast cell inhibition and depletion without impacting other KIT-dependent functions. CDX-622 is currently being studied in a Phase 1b proof of mechanism study in mild to moderate asthma to assess the impact of dual neutralization of SCF and TSLP.

Simplify High Yield ETF (NYSEARCA:CDX - Get Free Report) saw a significant increase in short interest in the month of March. As of March 13th, there was short interest totaling 366,043 shares, an increase of 1,869.9% from the February 26th total of 18,582 shares. Approximately 1.7% of the company's shares are sold short. Based on

AE Wealth Management LLC boosted its stake in shares of Simplify High Yield ETF (NYSEARCA:CDX) by 20.8% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 1,042,223 shares of the company's stock after acquiring an additional 179,543 shares during the period. AE Wealth Management LLC

NEW YORK--(BUSINESS WIRE)--Simplify Asset Management announces that it expects to deliver capital gains distributions across ten ETFs.

VettaFi recently sat down with Christopher Getter of Simplify Asset Management to discuss the role of private credit in portfolios and the unique structure of the Simplify Private Credit Strategy ETF (PCR), which is currently yielding 12.27%.